Has Tracy Morgan publicly confirmed using Ozempic?

Yes. In 2024, Tracy Morgan made public statements confirming his use of Ozempic for type 2 diabetes management, describing concurrent weight loss as part of his treatment experience.

Is Ozempic approved for weight loss?

Ozempic (semaglutide) is FDA-approved for type 2 diabetes, not weight loss. Wegovy, which contains the same active ingredient at a higher dose (2.4 mg), is the FDA-approved formulation for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity.

How much weight can a T2D patient expect to lose on Ozempic?

Clinical trials show T2D patients on Ozempic 1 mg lose approximately 4.5 to 6.5 kg (10 to 14 lbs) over 30 to 56 weeks. Individual results vary based on baseline weight, diet, physical activity, and metabolic factors.

What happens if you stop taking Ozempic?

Extension studies show that patients regain roughly two-thirds of lost weight within a year of stopping semaglutide. In T2D patients, HbA1c levels also tend to return toward pre-treatment values. This reflects the chronic nature of the conditions being treated.

Does Ozempic reduce heart attack risk?

The SUSTAIN 6 trial demonstrated a 26% reduction in major adverse cardiovascular events (cardiovascular death, nonfatal heart attack, nonfatal stroke) with semaglutide in T2D patients over approximately two years.

The Medical Takeaways from Tracy Morgan's GLP-1 Story

By HealthRX Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

Tracy Morgan's Public Disclosure

Tracy Morgan, the Emmy-nominated comedian and actor best known for 30 Rock and Saturday Night Live, has been open about his type 2 diabetes diagnosis for years. In 2024, Morgan publicly discussed his use of Ozempic, confirming that the medication was prescribed for diabetes management. He described noticeable weight loss alongside improved blood sugar control, a combination that tracks with the drug's clinical profile.

What makes Morgan's disclosure valuable from a medical-education standpoint is its ordinariness. He did not frame the medication as a vanity tool or a shortcut. He described a chronic disease and a treatment his doctor recommended. That framing matters, because the public conversation around GLP-1 medications has often drifted toward celebrity weight-loss narratives while obscuring the drugs' primary therapeutic purpose.

What Is Ozempic, and Why Was It Prescribed?

Ozempic is a brand name for semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA in 2017 for the treatment of type 2 diabetes in adults. It is administered as a once-weekly subcutaneous injection in doses of 0.25 mg, 0.5 mg, 1 mg, and 2 mg.

GLP-1 receptor agonists mimic a naturally occurring hormone (GLP-1) released by the gut after eating. The drug binds to GLP-1 receptors on pancreatic beta cells, stimulating glucose-dependent insulin secretion. In plain language: it helps the pancreas release insulin when blood sugar is high, but does not force insulin release when glucose levels are normal. This glucose-dependent mechanism is why hypoglycemia risk is low with GLP-1 monotherapy compared to older diabetes drugs like sulfonylureas.

Beyond glycemic control, semaglutide slows gastric emptying and acts on appetite-regulating centers in the hypothalamus, reducing hunger signals. These effects produce clinically meaningful weight loss in most patients. The SUSTAIN clinical trial program demonstrated average weight reductions of 4.5 to 6.5 kg (roughly 10 to 14 lbs) over 30 to 56 weeks at the 1 mg dose in patients with T2D.

At a glance

Drug: Ozempic (semaglutide), once-weekly injectable GLP-1 receptor agonist
FDA-approved indication: Type 2 diabetes (as adjunct to diet and exercise)
Mechanism: Glucose-dependent insulin secretion, slowed gastric emptying, central appetite suppression
Tracy Morgan's confirmed use: Diabetes management with concurrent weight loss
Typical T2D weight loss: 4.5 to 6.5 kg over 30 to 56 weeks (1 mg dose)
HbA1c reduction: 1.2 to 1.8 percentage points (across SUSTAIN trials)

Medical Takeaway 1: GLP-1s Were Built for Diabetes First

The HealthRX Medical Team wants to emphasize a point that the celebrity Ozempic conversation consistently undersells. Semaglutide was developed, tested, and approved as a diabetes medication. Weight loss in T2D patients is a secondary benefit that happens to be large enough to be clinically significant.

Morgan's public record reflects this. He described Ozempic in the context of a diabetes diagnosis, not as a weight-management strategy. For the roughly 37 million Americans living with diabetes (90 to 95% of whom have type 2), this distinction is not academic. Insurance coverage, prior authorization, and drug availability all hinge on indication. GLP-1 medications prescribed for T2D follow a different reimbursement pathway than the same molecules prescribed for obesity under brand names like Wegovy.

Patients with T2D who see Morgan's story and ask their doctor about Ozempic are asking the right question for the right reason. The American Diabetes Association's Standards of Care positions GLP-1 receptor agonists as a preferred second-line agent (after metformin) for patients with T2D, particularly those with established cardiovascular disease or high cardiovascular risk.

Medical Takeaway 2: Weight Loss in T2D Patients Differs from Weight Loss in Obesity-Only Patients

A common misconception: that everyone on semaglutide will lose dramatic amounts of weight. The clinical data tells a more specific story.

In SUSTAIN 6, patients with T2D on semaglutide 1 mg lost an average of approximately 4.9 kg over two years. Compare that to the STEP 1 trial, where non-diabetic adults with obesity on semaglutide 2.4 mg (the Wegovy dose) lost an average of 14.9% of body weight over 68 weeks.

The difference is partly dose-related (Ozempic maxes at 2 mg; Wegovy goes to 2.4 mg) and partly biological. Insulin resistance and compensatory metabolic mechanisms in T2D can blunt weight-loss magnitude. The HealthRX Medical Team's read: patients with type 2 diabetes should expect meaningful but moderate weight reduction on Ozempic, typically 5 to 10% of body weight. That range is still clinically significant. A meta-analysis in The Lancet found that even 5% weight loss in T2D patients is associated with improved glycemic markers, reduced blood pressure, and favorable lipid shifts.

Morgan's reported experience, where both diabetes control and weight loss occurred together, matches the expected clinical profile well.

Medical Takeaway 3: The Side-Effect Profile Is Real and Predictable

GLP-1 receptor agonists carry a well-characterized gastrointestinal side-effect profile. The most common adverse events in semaglutide trials include:

Nausea: reported in 15 to 20% of patients, usually worst during dose titration
Vomiting: 5 to 9%
Diarrhea: 8 to 12%
Constipation: 5 to 7%
Abdominal pain: 6 to 8%

These GI effects tend to peak during the first 4 to 8 weeks and during dose escalation, then diminish as the body adjusts. The standard titration schedule (starting at 0.25 mg for 4 weeks, then 0.5 mg for at least 4 weeks, before advancing) exists specifically to reduce GI intolerance.

More serious but less common risks include pancreatitis (rare, <1%), gallbladder events (cholelithiasis in roughly 1.5 to 2% of patients in longer trials), and a boxed warning for medullary thyroid carcinoma based on rodent data. The drug is contraindicated in patients with a personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia syndrome type 2.

The HealthRX Medical Team's clinical note: celebrities rarely discuss side effects publicly, which can create an unrealistic perception of tolerability. Patients starting Ozempic should plan for a titration period where nausea is likely. Eating smaller meals, avoiding high-fat foods, and staying hydrated are standard recommendations during dose escalation.

Medical Takeaway 4: Discontinuation Is the Conversation Nobody Has Publicly

One of the least-discussed aspects of GLP-1 therapy, in celebrity circles or otherwise, is what happens when the medication stops. The STEP 1 extension trial showed that participants who discontinued semaglutide regained approximately two-thirds of lost weight within one year of stopping. HbA1c values in T2D patients tend to drift back toward pre-treatment levels as well.

This is not a flaw in the drug. It reflects the biology of the diseases it treats. Type 2 diabetes and obesity are chronic conditions. Removing the pharmacological intervention allows underlying pathophysiology to reassert itself. The clinical parallel is straightforward: stopping a blood pressure medication does not cure hypertension, and stopping semaglutide does not cure metabolic disease.

For patients like Morgan, whose primary indication is T2D, the standard of care generally assumes long-term use unless contraindications emerge or better alternatives become available. The HealthRX Medical Team considers this the most important lesson from any celebrity GLP-1 story: these medications work while you take them. Patients and prescribers should discuss long-term plans from the outset.

Medical Takeaway 5: Cardiovascular Benefit Is an Underreported Bonus

Semaglutide has demonstrated cardiovascular benefit in patients with T2D. In SUSTAIN 6, semaglutide reduced the composite endpoint of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke by 26% compared to placebo over 2.1 years. The SELECT trial later extended evidence of cardiovascular risk reduction to patients with obesity and established cardiovascular disease, even without diabetes.

For T2D patients, cardiovascular disease is the leading cause of death. The American Heart Association estimates that adults with T2D are two to four times more likely to die from heart disease than adults without diabetes. A medication that simultaneously lowers blood sugar, reduces weight, and cuts cardiovascular events represents a genuine clinical advance for this population.

Morgan has not publicly discussed cardiovascular outcomes, and the HealthRX Medical Team would not speculate about his individual risk profile. But the population-level data is clear: for T2D patients with cardiovascular risk factors, GLP-1 receptor agonists offer benefits that extend well beyond glycemic control.

What Non-Celebrity Patients Should Take from This

Tracy Morgan's Ozempic disclosure is useful precisely because it is uncomplicated. A patient with type 2 diabetes takes a medication approved for type 2 diabetes. He reports the expected results: better blood sugar management and weight loss. No miracle claims. No dramatic before-and-after framing.

The HealthRX Medical Team encourages patients considering GLP-1 therapy to bring three questions to their prescriber:

Is my primary goal glycemic control, weight management, or both? The answer affects which formulation and dose is appropriate.
What is the plan if I need to stop this medication? Discussing discontinuation strategies upfront prevents surprises later.
Am I on the right titration schedule? Rushing dose escalation is the most common cause of avoidable GI side effects.

GLP-1 receptor agonists are effective, well-studied medications with a growing evidence base. They are not magic. They work within predictable parameters, and the clinical literature describes those parameters clearly.

Frequently asked questions

›